Novartis’ Cosentyx meets primary endpoint at Week 16 in PREVENT trial

This article was originally published here

The PREVENT trial is assessing the efficacy and safety of Cosentyx compared to placebo with the primary endpoint being ASAS40 at Week 16. All the secondary endpoints of

The post Novartis’ Cosentyx meets primary endpoint at Week 16 in PREVENT trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply